UNI-EN 26:Analysis of potential acquisition opportunities on the territory of the Republic of Serbia
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 26 | / | 2023 | |||||||
| Date of issue: | 2023-06-01 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Analysis of potential acquisition opportunities on the territory of the Republic of Serbia | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (the Company) notifies that at its meeting the Board of Directors decided to conduct a detailed analysis of potential opportunities for acquisition of shares in the capital of companies engaged in the production and/or marketing of medicinal products, food supplements, medical devices and/or other goods of importance to human health on the territory of the Republic of Serbia. The Board of Directors has authorized the representatives of the Company to carry out all necessary legal and factual actions related to the evaluation, investigation and initial negotiations for the implementation of a possible acquisition of a joint participation and/or a majority stake in the capital of such companies. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| МА_Serbia_2023_espi_26.pdf МА_Serbia_2023_espi_26.pdf | Analysis of potential acquisition opportunities on the territory of the Republic of Serbia | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2023-06-01 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 13.0 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
